About us Pricing ContactSubscribe

P

Paolo A. Ascierto

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"ORCID https://orcid.org/0000-0002-8322-475X

h-index

—

Publications

—

Citations

—

i10-index

—

Impact (2-yr)

—

Top Publications

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

New England Journal of Medicine20158,055 citations

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

New England Journal of Medicine20117,653 citations

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Journal of Clinical Oncology20192,871 citations

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology20152,648 citations

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

The Lancet Oncology20151,554 citations

Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours

The Journal of Pathology20131,337 citations

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

European Journal of Cancer2017555 citations